EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Robert Gilmore, Richard Fernandes, Imogen Hartley, Arteen Arzivian, Rupert Leong, Bridgette Andrew, Abhinav Vasudevan, Tessa Greeve, Gregory Thomas Moore, Steven Kim, Daniel Lightowler, Abhey Singh und 12 weitere

Intestinal Research · 30.07.2025 · 23 (3) · 347-357

DOI: 10.5217/ir.2024.00127 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Intestinal Research, erschienen am 30.07.2025. Verfasst von Robert Gilmore und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Mater Hospital, Brisbane, Australia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population.

Methods

Patients that commenced upadacitinib for moderate-to-severe ulcerative colitis from September 2022 until March 2023 were identified at 13 inflammatory bowel disease centers across Australia. Clinical, biochemical, endoscopic, and intestinal ultrasound outcomes were recorded retrospectively at baseline, week 8, and week 16.

Results

One hundred and fifty-two patients (61 female [40%], median age 38 years [interquartile range, 28–50]) were included. The primary endpoint of clinical remission was met in 79% at week 8, and 84% at week 16. A total of 42 patients (28%) with prior tofacitinib exposure were included. No significant difference in clinical remission was observed by week 16 between tofacitinib experienced compared to tofacitinib naïve patients (86% vs. 84%, P= 0.67). Complete intestinal ultrasound data was available for 36 patients, showing transmural remission in 64% at week 8 and 81% at week 16, with a decrease in median bowel wall thickness of 2.3 mm and 2.4 mm, respectively.

Conclusions

Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16.

Schlagwörter

Stichwörter der Autor:innen

Intestinal ultrasoundJanus kinase inhibitorsTofacitinibUlcerative colitisUpadacitinib

Autor:innen und Institutionen

  • Department of Gastroenterology, Mater Hospital, Brisbane, Australia.
  • Mater Research Institute, The University of Queensland, South Brisbane, Australia.
  • Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Australia.
  • Department of Gastroenterology, Macquarie University Hospital, Sydney, Australia.
  • Department of Gastroenterology, Eastern Health, Melbourne, Australia.
  • Monash University, Eastern Health Clinical School, Melbourne, Australia.

Zitieren

APA

Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G. T., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopaul, K., Han, S., Bryant, R., West, J., Segal, J., …, & Begun, J. (2025). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research, 23(3), 347-357. https://doi.org/10.5217/ir.2024.00127

Vancouver

Gilmore R, Fernandes R, Hartley I, Arzivian A, Leong R, Andrew B, et al. Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research. 2025;23(3):347-357. doi:10.5217/ir.2024.00127

BibTeX
@article{Gilmore2025,
  author = {Gilmore, Robert and Fernandes, Richard and Hartley, Imogen and Arzivian, Arteen and Leong, Rupert and Andrew, Bridgette and Vasudevan, Abhinav and Greeve, Tessa and Moore, Gregory Thomas and Kim, Steven and Lightowler, Daniel and Singh, Abhey and Mahy, Gillian and Mithanthaya, Aditya and Venugopaul, Kannan and Han, Sangwoo and Bryant, Robert and West, Jack and Segal, Jonathan and Christensen, Britt and Corte, Crispin and Ding, Nik and An, Yoon-Kyo and Begun, Jakob},
  title = {Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study},
  journal = {Intestinal Research},
  year = {2025},
  volume = {23},
  number = {3},
  pages = {347--357},
  doi = {10.5217/ir.2024.00127}
}
Kostenlos starten →